The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to ...cancer. Already there are promising indications, from clinical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patients with germline
BRCA1
or
BRCA2
gene mutations, that this approach could be beneficial. We discuss the biological rationale for BRCA-PARP synthetic lethality, how the synthetic lethal approach is being assessed in the clinic, and how mechanisms of resistance are starting to be dissected. Applying the synthetic lethal concept to target non-
BRCA
-mutant cancers also has clear potential, and we discuss how some of the principles learned in developing PARP inhibitors might also drive the development of additional genetic approaches.
BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) ...is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.
Full text
Available for:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Micro-Abstract The management of patients with oligometastatic non–small-cell lung cancer (NSCLC) is controversial. The findings of this metaanalysis of 757 oligometastatic NSCLC patients treated ...with ablative treatments to all sites of disease suggest that the timing of metastatic disease (synchronous vs. metachronous) and intrathoracic nodal status are key determinants of long-term survival. A risk classification scheme is proposed to guide clinical decision-making.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target ...cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
The applicability of Raman spectroscopy for phase discrimination of metal-organic frameworks (MOFs) has been demonstrated with F4_MIL-140A(Ce) and F4_UiO-66(Ce); analogues prepared from the same ...metal and ligand sources. Each analogue exhibits unique Raman peaks, with significant differences in the low frequency region, which is more sensitive to structural variations. Non-invasive Raman monitoring of F4_MIL-140A(Ce) synthesis indicated evolution of a unique MOF Raman peak with reaction progress; conversion of this Raman signal to extent of crystallisation was in good agreement with reported reaction kinetics determined
a synchrotron diffraction method. Additionally, Raman spectroscopy indicated initial rapid consumption of the nitric acid modulator present in the reaction coinciding with an expected high probability of nucleation. Raman spectroscopy is a promising technique for rapid screening of MOFs and can be used to study the mechanism of their formation
with kinetic insight into both the solution and solid phases of the reaction medium.
PDF
